EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Interaction between tacrolimus and calcium channel blockers based on CYP3A5 genotype in Chinese renal transplant recipients

Huiying Zong, Yundi Zhang, Fengxi Liu, Xiaoming Zhang, Yilei Yang, Xiaohong Cao, Yue Li, Anan Li, Penglin Zhou, Rui Gao, Yan Li

Frontiers in Pharmacology · 29.08.2024 · 15

DOI: 10.3389/fphar.2024.1458838 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.08.2024. Verfasst von Huiying Zong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Shandong Provincial Qianfoshan Hospital, Shandong University of Traditional Chinese Medicine, Shandong Medicine and …. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the effect of calcium channel blockers (CCBs) on tacrolimus blood concentrations in renal transplant recipients with different CYP3A5 genotypes.

Methods

This retrospective cohort study included renal transplant recipients receiving tacrolimus-based immunosuppressive therapy with or without CCBs in combination. Patients were divided into combination and control groups based on whether or not they were combined with CCBs, and then further analyzed according to the type of CCBs (nifedipine/amlodipine/felodipine). Propensity score matching was conducted for the combination and the control groups using SPSS 22.0 software to reduce the impact of confounding factors. The effect of different CCBs on tacrolimus blood concentrations was evaluated, and subgroup analysis was performed according to the patients’ CYP3A5 genotypes to explore the role of CYP3A5 genotypes in drug-drug interactions between tacrolimus and CCBs.

Results

A total of 164 patients combined with CCBs were included in the combination groups. After propensity score matching, 83 patients with nifedipine were matched 1:1 with the control group, 63 patients with felodipine were matched 1:2 with 126 controls, and 18 patients with amlodipine were matched 1:3 with 54 controls. Compared with the controls, the three CCBs increased the dose-adjusted trough concentration (C 0 /D) levels of tacrolimus by 41.61%–45.57% ( P < 0.001). For both CYP3A5 expressers ( CYP3A5*1*1 or CYP3A5*1*3 ) and non-expressers ( CYP3A5*3*3 ), there were significant differences in tacrolimus C 0 /D between patients using felodipine/nifedipine and those without CCBs ( P < 0.001). However, among CYP3A5 non-expressers, C 0 /D values of tacrolimus were significantly higher in patients combined with amlodipine compared to the controls ( P = 0.001), while for CYP3A5 expressers, the difference in tacrolimus C 0 /D values between patients with amlodipine and without was not statistically significant ( P = 0.065).

Conclusion

CCBs (felodipine/nifedipine/amlodipine) can affect tacrolimus blood concentration levels by inhibiting its metabolism. The CYP3A5 genotype may play a role in the drug interaction between tacrolimus and amlodipine. Therefore, genetic testing for tacrolimus and therapeutic drug monitoring are needed when renal transplant recipients are concurrently using CCBs.

Schlagwörter

Stichwörter der Autor:innen

C0/DCYP3A5 polymorphismcalcium channel blockersrenal transplanttacrolimus

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Shandong Provincial Qianfoshan Hospital, Shandong University of Traditional Chinese Medicine, Shandong Medicine and Health Key Laboratory of Clinical Pharmacy, Jinan, China.
  • Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Dev…
  • Urinary surgery, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, China.

Zitieren

APA

Zong, H., Zhang, Y., Liu, F., Zhang, X., Yang, Y., Cao, X., Li, Y., Li, A., Zhou, P., Gao, R., & Li, Y. (2024). Interaction between tacrolimus and calcium channel blockers based on CYP3A5 genotype in Chinese renal transplant recipients. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1458838

Vancouver

Zong H, Zhang Y, Liu F, Zhang X, Yang Y, Cao X, et al. Interaction between tacrolimus and calcium channel blockers based on CYP3A5 genotype in Chinese renal transplant recipients. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1458838

BibTeX
@article{Zong2024,
  author = {Zong, Huiying and Zhang, Yundi and Liu, Fengxi and Zhang, Xiaoming and Yang, Yilei and Cao, Xiaohong and Li, Yue and Li, Anan and Zhou, Penglin and Gao, Rui and Li, Yan},
  title = {Interaction between tacrolimus and calcium channel blockers based on CYP3A5 genotype in Chinese renal transplant recipients},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1458838}
}
Kostenlos starten →